Temecula, CA / March 18, 2014 / The federal government has recently signed off on a study aimed at using marijuana as a treatment for veterans with post-traumatic stress disorder, a development that drug researchers are hailing as a major shift in U.S. drug policy.
The Department of Health and Human Services' decision surprised medical marijuana advocates who have been struggling for decades to secure federal approval for research into the drug's medical uses.
The initial proposal from the University of Arizona was long ago cleared by the Food and Drug Administration, but researchers had been unable to purchase marijuana from the National Institute on Drug Abuse. The agency's Mississippi research farm is the only federally-sanctioned source of the drug.
In correspondence last week, HHS cleared the purchase of medical marijuana by the studies' chief financial backer, the Multidisciplinary Association for Psychedelic Studies, which is supporting medical research and legalization of marijuana and other drugs.
"MAPS has been working for over 22 years to start marijuana drug development research, and this is the first time we've been granted permission to purchase marijuana from NIDA," the group said in a statement. The government has never before approved medical research involving smoked or vaporized marijuana, according to MAPS.
While more than a million Americans taking medical marijuana, usually for chronic pain, rigorous medical research into the drug's effects has been limited, in part due to federal restrictions.
Sisley's study will measure the effects of several different potencies of smoked or vaporized marijuana in treating symptoms of PTSD in 50 veterans.
The US Veterans Administration estimates between 11 to 20 percent of soldiers who served in the recent Iraq and Afghanistan wars have PTSD, which can cause anxiety, flashbacks, depression and sleep deprivation. Approximately 7.7 million American adults are estimated to have the disorder.Physicians worldwide have long speculated that marijuana could be used to calm parts of the brain linked to overstimulation and anxiety, though little formal research has been conducted.
XTRM Company President Stated "We feel its important for our shareholders to be updated with the progress regarding Hemp and Medical Marijuana. Announcements of studies such as this show that we are on the right path with XTRM Cannabis Ventures. XTRM has begun starting its Hemp to Biodiesel program and plans to build a Medical Marijuana Cultivation center as laws permit."
About Extreme Biodiesel and XTRM Cannabis Ventures
Extreme Biodiesel (PINK:XTRM) is an alternative fuel and recycling company. Our mission is to provide a cost-effective, high-quality alternative diesel fuel, create "green" jobs, reduce the environmental impact of fossil fuels and diminish US reliance on foreign oil. Extreme Biodiesel is currently repositioning itself into a holdings corporation with focuses on Bio Diesel, Real Estate, Technology and Cannabis SectorsXTRM Cannabis Ventures is a wholly owned subsidiary of Extreme Biodiesel focused in the sector of Medical Marijuana, Cannabis and Hemp related products.
XTRM Cannabis Ventures Disclaimer
The Company would like to assure all investors that in all cannabis related actions the Company is conferring with counsel to be sure any business activities are deemed legal. XTRM advises all investors to see the website being developed at http://xtrmcannabisventures.comInvestor Relations Contact
Safe Harbor DisclaimerForward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. XTRM is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
Release ID: 36616